Anthera Pharmaceuticals (ANTH) is seeing a big move Monday, as the company’s shares are up 34% on optimism regarding its symposium on Systemic Lupus Erythematosus (SLE) at 3:30 PM on Wednesday, January 14th at the Mystic Hotel in San Francisco, CA.
Anthera Pharmaceuticals, currently valued at $53.68 million, has a median Wall Street price target of $5.00. Approximately 2.8 million shares have already changed hands, which dwarfs the average volume of 146.416K.
In the past 52 weeks, shares of Hayward, California-based biopharmaceutical firm have traded between a low of $1.46 and a high of $3.79 with the 50-day MA and 200-day MA located at $1.82 and $2.31 levels, respectively. Additionally, shares of ANTH have a Relative Strength Index (RSI) and MACD indicator of 68.89 and +0.18, respectively.
Anthera Pharmaceuticals currently prints a one year loss of about 48%.
ANTH recently traded at $2.33, up 58 cents.
Hot biotech IPO Kite Kite Pharma, Inc. (KITE) printed a new high Monday, up 12% to $67.89, after the Santa Monica, Calif.-based company said it inked a deal with Amgen Inc (AMGN) to develop and commercialize the next generation of novel Chimeric Antigen Receptor T cell immunotherapies. The deal is worth up to $585 million.
Kite Pharma said it will host a live conference call and webcast today at 4 p.m. ET to discuss the transaction.
Shares of Kite, which IPO-d in June at $17 per share, are up 56.39% on the month. The stock has risen to its third consecutive new all-time high.
3D Systems (DDD) had its price target lowered to $42 from $50 by Stifel in a research note issued on Monday. The equity research firm, which maintains a ‘Buy’ rating on the name, said it views the stock as representing an attractive reward to risk at current levels on the expectation recent execution issues were transitory with a resulting period of accelerating organic growth.
In other DDD news this morning, the company announced that it acquired U.K. based 3D printer maker botObjects. 3D Systems did not disclose the terms of the transaction, but said it expects it to be accretive to its 2015 results.
On valuation measures, 3D Systems Corporation shares are currently priced at 154.16x this year’s forecasted earnings. Ticker has a PEG and forward P/E ratio of 2.04 and 29.38, respectively. Price/Sales for the same period is 5.81 while EPS is $0.20. Currently there are 8 analysts that rate DDD a ‘Buy’, 14 rate it a ‘Hold’. 2 analysts rate it a ‘Sell’. DDD has a median Wall Street price target of $42.50 with a high target of $73.00.
In the past 52 weeks, shares of the Sunnyvale, California-based company have traded between a low of $27.46 and a high of $97.14 and are now at $30.52. Shares are down 66% year-over-year.
Shares of Inphi Corporation (IPHI) are up $1.89, or 10.65%, at $19.63, after the company this morning had its price target raised to $26 from $21 at Northland Capital.
IPHI has a t-12 forward P/E ratio of 20.26. Price/Sales for the same period is 5.04 while EPS is ($0.21). Currently ticker boasts just five ‘Buy’ endorsements, compared to 2 tepid ‘Holds’. Inphi has a median Wall Street price-per-share target of $20 with a high target of $23.
The average volume for the $727M market cap company has been 329K shares per day over the past 30 days. In the past 52 weeks, shares of Inphi Corporation have traded between a low of $10.87 and a high of $19.69. Shares are up 52.99% year-over-year.
The chart below shows where the equity has traded over the last 12 months.
Disclaimer: This page contains affiliate links. If you choose to make a purchase after clicking a link, we may receive a commission at no additional cost to you. Thank you for your support!